In Brief: Copley Pharmaceutical
This article was originally published in The Tan Sheet
Copley Pharmaceutical: Asks FDA not to grant three-year market exclusivity to Pharmacia & Upjohn for the sale of OTC Rogaine baldness treatment in a recent letter. Copley was close to having its generic minoxidil product approved for prescription sale when Rogaine achieved OTC status on Feb. 12; since then, Copley said, the company has been preparing new labeling and packaging to reflect the switch. Copley noted that it would be "severely prejudiced if the FDA permits Upjohn to continue to exploit procedural devices to extend its control over the sale of minoxidil." Copley's letter supports a citizen petition previously filed by Hyman, Phelps & McNamara...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC